Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 101

1.

Current state and future perspective of drug repurposing in malignant glioma.

Siegelin MD, Schneider E, Westhoff MA, Wirtz CR, Karpel-Massler G.

Semin Cancer Biol. 2019 Nov 14. pii: S1044-579X(19)30138-5. doi: 10.1016/j.semcancer.2019.10.018. [Epub ahead of print] Review.

PMID:
31734137
2.

Present and potential future adjuvant issues in high-grade astrocytic glioma treatment.

Lefranc F, Rynkowski M, DeWitte O, Kiss R.

Adv Tech Stand Neurosurg. 2009;34:3-35. Review.

PMID:
19368079
3.

Overcoming the blood-brain tumor barrier for effective glioblastoma treatment.

van Tellingen O, Yetkin-Arik B, de Gooijer MC, Wesseling P, Wurdinger T, de Vries HE.

Drug Resist Updat. 2015 Mar;19:1-12. doi: 10.1016/j.drup.2015.02.002. Epub 2015 Mar 6. Review.

PMID:
25791797
4.

Drug Repurposing of Metabolic Agents in Malignant Glioma.

Seliger C, Hau P.

Int J Mol Sci. 2018 Sep 14;19(9). pii: E2768. doi: 10.3390/ijms19092768. Review.

5.

Repurposed Drugs as Potential Therapeutic Candidates for the Management of Alzheimer's Disease.

Shoaib M, Kamal MA, Rizvi SMD.

Curr Drug Metab. 2017;18(9):842-852. doi: 10.2174/1389200218666170607101622. Review.

PMID:
28595531
6.

Drug Repositioning in Glioblastoma: A Pathway Perspective.

Tan SK, Jermakowicz A, Mookhtiar AK, Nemeroff CB, Schürer SC, Ayad NG.

Front Pharmacol. 2018 Mar 16;9:218. doi: 10.3389/fphar.2018.00218. eCollection 2018. Review.

7.

Current status of local therapy in malignant gliomas--a clinical review of three selected approaches.

Juratli TA, Schackert G, Krex D.

Pharmacol Ther. 2013 Sep;139(3):341-58. doi: 10.1016/j.pharmthera.2013.05.003. Epub 2013 May 18. Review.

PMID:
23694764
8.

[Development of antituberculous drugs: current status and future prospects].

Tomioka H, Namba K.

Kekkaku. 2006 Dec;81(12):753-74. Review. Japanese.

PMID:
17240921
9.

Drug repurposing for the treatment of glioblastoma multiforme.

Abbruzzese C, Matteoni S, Signore M, Cardone L, Nath K, Glickson JD, Paggi MG.

J Exp Clin Cancer Res. 2017 Nov 28;36(1):169. doi: 10.1186/s13046-017-0642-x. Review.

10.

New treatment strategies for malignant gliomas.

Sathornsumetee S, Rich JN.

Expert Rev Anticancer Ther. 2006 Jul;6(7):1087-104. Review.

PMID:
16831080
11.

Drug Discovery and Development for Pain.

Chaplan SR, Eckert III WA, Carruthers NI.

In: Kruger L, Light AR, editors. Translational Pain Research: From Mouse to Man. Boca Raton (FL): CRC Press/Taylor & Francis; 2010. Chapter 18.

12.

A High-Throughput Screening Approach To Repurpose FDA-Approved Drugs for Bactericidal Applications against Staphylococcus aureus Small-Colony Variants.

Trombetta RP, Dunman PM, Schwarz EM, Kates SL, Awad HA.

mSphere. 2018 Oct 31;3(5). pii: e00422-18. doi: 10.1128/mSphere.00422-18.

13.

[The sodium pump could constitute a new target to combat glioblastomas].

Lefranc F, Mijatovic T, Kiss R.

Bull Cancer. 2008 Mar;95(3):271-81. doi: 10.1684/bdc.2008.0597. French.

14.

Central nervous system.

Adamson DC, Rasheed BA, McLendon RE, Bigner DD.

Cancer Biomark. 2010;9(1-6):193-210. doi: 10.3233/CBM-2011-0177. Review.

PMID:
22112477
15.

Novel therapies for malignant gliomas: a local affair?

Rainov NG, Söling A, Heidecke V.

Neurosurg Focus. 2006 Apr 15;20(4):E9. Review.

PMID:
16709040
16.

The role of autophagy in sensitizing malignant glioma cells to radiation therapy.

Zhuang W, Qin Z, Liang Z.

Acta Biochim Biophys Sin (Shanghai). 2009 May;41(5):341-51. Review.

17.

Proteasome inhibition with bortezomib induces cell death in GBM stem-like cells and temozolomide-resistant glioma cell lines, but stimulates GBM stem-like cells' VEGF production and angiogenesis.

Bota DA, Alexandru D, Keir ST, Bigner D, Vredenburgh J, Friedman HS.

J Neurosurg. 2013 Dec;119(6):1415-23. doi: 10.3171/2013.7.JNS1323. Epub 2013 Oct 4.

18.

Targeting Gliomas: Can a New Alkylating Hybrid Compound Make a Difference?

Pinheiro R, Braga C, Santos G, Bronze MR, Perry MJ, Moreira R, Brites D, Falcão AS.

ACS Chem Neurosci. 2017 Jan 18;8(1):50-59. doi: 10.1021/acschemneuro.6b00169. Epub 2016 Oct 11.

PMID:
27665765
19.

Interleukin-13 receptor-directed cytotoxin for malignant glioma therapy: from bench to bedside.

Husain SR, Puri RK.

J Neurooncol. 2003 Oct;65(1):37-48. Review.

PMID:
14649884
20.

Cancer stem cells in glioblastoma--molecular signaling and therapeutic targeting.

Huang Z, Cheng L, Guryanova OA, Wu Q, Bao S.

Protein Cell. 2010 Jul;1(7):638-55. doi: 10.1007/s13238-010-0078-y. Epub 2010 Jul 29. Review.

Supplemental Content

Support Center